Pro Medicus Stock Earnings Reports

Pro Medicus delivered a record FY25 with strong top- and bottom-line growth driven by large new contracts, upgrades and renewals. Revenue rose ~32% and profit after tax ~40%, with underlying EBIT and margins expanding (margin ~74%). Sales highlights include seven new contracts (minimums totalling $520m), two renewals ($130m) and material upgrades (e.g., NYU and Duke archive migrations). The company emphasized its scalable transaction-based, cloud-only model and proprietary streaming technology (Visage 7) as key competitive advantages for speed, clinician efficiency and handling rapidly growing image dataset sizes. Forward minimum revenue increased materially to about $948m (five-year window), providing strong annuity-like visibility. Product expansion continues: cardiology is rolling out (first implementations done, UC Health Colorado upcoming), digital pathology is being brought to market (target calendar-year release), and AI collaborations (e.g., breast AI with NYU) and Vision Pro integrations are advancing. Management reiterated competitive differentiation via full-cloud deployments at scale, fast implementation capability, and a strategy to grow both footprint and transaction volumes from existing clients. OpEx/headcount growth for FY26 will be broadly in line with FY25 to support sales, implementations and R&D. Geography focus remains North America as primary market with Europe/Asia secondary opportunities.